--- title: "ProQR registers resale of up to 3,030,303 shares for a selling shareholder" url: "https://aibio.space/news/proqr-registers-resale-up-3-030-303-shares-selling-shareholder/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-07-15" section: "Financings" tickers: "NASDAQ:PRQR" source: "https://www.sec.gov/Archives/edgar/data/1612940/000110465926083906/tm2619566-4_424b5.htm" summary: "ProQR is registering 3,030,303 shares for resale by a holder the prospectus calls Ginkgo, issued in April 2026 under a share purchase agreement tied to a s" --- By the aibio.space news desk. Sources - [ProQR Therapeutics N.V. 424B5 (2026-07-15)](https://www.sec.gov/Archives/edgar/data/1612940/000110465926083906/tm2619566-4_424b5.htm) [PRQR](https://aibio.space/companies/proqr-therapeutics-n-v/) 2026-07-15 # ProQR registers resale of up to 3,030,303 shares for a selling shareholder Tickers [PRQR](https://aibio.space/companies/proqr-therapeutics-n-v/) ProQR is registering 3,030,303 shares for resale by a holder the prospectus calls Ginkgo, issued in April 2026 under a share purchase agreement tied to a services contract. ProQR receives none of the proceeds, and the prospectus gives no per-share price for the shares. ## Key facts - **Company**: ProQR Therapeutics N.V. (NASDAQ: PRQR) - **News type**: Financings - **Primary source**: [ProQR Therapeutics N.V. 424B5 (2026-07-15)](https://www.sec.gov/Archives/edgar/data/1612940/000110465926083906/tm2619566-4_424b5.htm) *A red price chart on a screen. CC0, via rawpixel. The picture shows the field, not the companies named.* ## The registration ProQR Therapeutics N.V. (Nasdaq: [PRQR](https://aibio.space/companies/proqr-therapeutics-n-v/)) filed a 424B5 prospectus on July 15, 2026 covering the resale of up to 3,030,303 ordinary shares by a selling shareholder. The prospectus identifies that holder as Ginkgo and ties the shares to a Share Purchase Agreement dated April 7, 2026 with Ginkgo Bioworks Holdings, Inc. ProQR says it is registering the shares because the agreement's registration rights require it, and that the registration "does not mean that the Selling Shareholder will offer or sell any of the Shares." ProQR receives none of the proceeds from sales by the holder. The company pays the registration costs, other than the holder's own counsel and advisers and any underwriting discounts or commissions. The holder may sell "any, all or none" of the shares, and ProQR says it does not know when or in what amount any sales would occur. ## The services contract behind the shares The share issue is linked to a services arrangement. On April 7, 2026, ProQR Therapeutics I B.V., a wholly owned subsidiary, signed a Master Services Agreement with Ginkgo Bioworks for autonomous lab, high-throughput data generation to support AI-enabled drug discovery for ProQR's Axiomer platform. The prospectus says ProQR I received a credit of $5,000,000 for services under that agreement. On the same date ProQR agreed to issue Ginkgo Bioworks Holdings the 3,030,303 shares and to register them for resale within ninety days. The prospectus gives no per-share price for the April issuance. It does not say what the holder paid in cash, if anything, for the shares. ## Dilution and the share base As of March 31, 2026, ProQR had 107,710,916 ordinary shares issued, of which 105,362,551 were outstanding and 2,348,365 were held as treasury shares. The Ginkgo shares are not the only recent issue. The prospectus says ProQR entered share purchase agreements with Eli Lilly and Company in September 2021, December 2022, October 2024 and June 2026, selling it 3,989,976, 9,381,586, 3,523,538 and 5,100,780 ordinary shares in those rounds. The prospectus warns that the share price is highly volatile. It notes that the stock reached a record high of $24.99 per share at the close on March 10, 2015, and fell as low as $0.56 per share on May 11, 2022. The last reported sale price before the filing was $1.81 on July 2, 2026. ## Capital raised and losses ProQR says it has raised €570.0 million in gross proceeds from public offerings of shares and private placements of equity securities. Its annual report on Form 20-F, filed March 12, 2026, shows revenue of €15.9 million in 2025, down from €18.9 million in 2024. Research and development costs rose to €44.7 million from €36.4 million, and the net loss widened to €42.2 million from €27.8 million. Cash used in operations was €52.8 million in 2025 and €36.4 million in 2024, according to the same report. The July prospectus does not state a current cash balance. It does report two raises in June 2026: 27,624,310 ordinary shares sold in a registered direct offering on June 26, 2026 for aggregate gross proceeds of approximately $50 million, and 5,100,780 ordinary shares sold to Lilly the same day for approximately $9.2 million, under a share purchase agreement dated June 25, 2026. ## Banks and advisers The prospectus names no underwriter, placement agent or financial adviser for this resale, and does not name the counsel of the selling shareholder. For ProQR, Goodwin Procter LLP of Boston passes on U.S. federal and New York law, and A&O Shearman LLP of Amsterdam passes on Dutch law, including the validity of the shares. KPMG Accountants N.V. is the auditor. Cantor Fitzgerald & Co. is ProQR's sales agent under a November 4, 2021 at-the-market agreement, which the share count excludes. ## What comes next ProQR cannot control whether or when the holder sells. Once the registration is effective, Ginkgo may sell some, all or none of the 3,030,303 shares at market or negotiated prices, and the prospectus gives no date for a sale. Any sale would add to a share base that already includes the recent Lilly issues and the June offering. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story PRQR ProQR Therapeutics N.V. NASDAQ · Netherlands Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/proqr-registers-resale-up-3-030-303-shares-selling-shareholder/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ProQR registers resale of up to 3,030,303 shares for a selling shareholder", 2026-07-15, https://aibio.space/news/proqr-registers-resale-up-3-030-303-shares-selling-shareholder/